{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:45:10Z","timestamp":1787003110049,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA193776"],"award-info":[{"award-number":["R01CA193776"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["X01HD100702-01"],"award-info":[{"award-number":["X01HD100702-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5UG1CA233249"],"award-info":[{"award-number":["5UG1CA233249"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex\u2019s Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children\u2019s Hospital of Philadelphia Frontier Programs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in pediatric patients. Weeks after an often mild or asymptomatic initial infection with SARS-CoV-2 children may present with a severe shock-like picture and marked inflammation. Children with MIS-C present with varying degrees of cardiovascular and hyperinflammatory symptoms. Here we perform a comprehensive analysis of the plasma proteome of more than 1400 proteins in children with SARS-CoV-2. We hypothesize that the proteome would reflect heterogeneity in hyperinflammation and vascular injury, and further identify pathogenic mediators of disease. We show that protein signatures demonstrate overlap between MIS-C, and the inflammatory syndromes macrophage activation syndrome (MAS) and thrombotic microangiopathy (TMA). We demonstrate that PLA2G2A is an important marker of MIS-C that associates with TMA. We find that IFN\u03b3 responses are dysregulated in MIS-C patients, and that IFN\u03b3 levels delineate clinical heterogeneity.<\/jats:p>","DOI":"10.1038\/s41467-021-27544-6","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T06:04:11Z","timestamp":1639116251000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction"],"prefix":"10.1038","volume":"12","author":[{"given":"Caroline","family":"Diorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan","family":"Shraim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Vella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine R.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1555-0713","authenticated-orcid":false,"given":"Amy E.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"Oldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Canna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Henrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin O.","family":"McNerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Balamuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakkapong","family":"Burudpakdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8069-3393","authenticated-orcid":false,"given":"Tomas","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Farrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0439-402X","authenticated-orcid":false,"given":"Michele P.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen E.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1956","authenticated-orcid":false,"given":"E. John","family":"Wherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7373-8987","authenticated-orcid":false,"given":"David T.","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Bassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"27544_CR1","unstructured":"Verdoni L, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;(Published online May 13, 2020 https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)31103-X\/fulltext)."},{"key":"27544_CR2","unstructured":"Riphagen S, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;(published online May 7, 2020 https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)31094-1\/fulltext)."},{"key":"27544_CR3","unstructured":"Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet. 2020;(Published online May 13, 2020 https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(20)31129-6\/fulltext)."},{"key":"27544_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJMoa2021680","volume":"383","author":"LR Feldstein","year":"2020","unstructured":"Feldstein, L. R. et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 383, 334\u2013346 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27544_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2020.09.016","volume":"183","author":"CR Consiglio","year":"2020","unstructured":"Consiglio, C. R. et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 183, 968\u2013981.e967 (2020).","journal-title":"Cell"},{"key":"27544_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41577-020-0367-5","volume":"20","author":"AH Rowley","year":"2020","unstructured":"Rowley, A. H. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat. Rev. Immunol. 20, 453\u2013454 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"27544_CR7","doi-asserted-by":"publisher","first-page":"e144554","DOI":"10.1172\/JCI144554","volume":"131","author":"A Esteve-Sole","year":"2021","unstructured":"Esteve-Sole, A. et al. Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease. J. Clin. Investig. 131, e144554 (2021).","journal-title":"J. Clin. Investig."},{"key":"27544_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jama.2021.0694","volume":"325","author":"N Ouldali","year":"2021","unstructured":"Ouldali, N. et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 325, 855\u2013864 (2021).","journal-title":"JAMA"},{"key":"27544_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.cjco.2020.09.004","volume":"2","author":"MD Elias","year":"2020","unstructured":"Elias, M. D. et al. Management of multisystem inflammatory syndrome in children associated with COVID-19: a survey from the international Kawasaki disease registry. CJC Open. 2, 632\u2013640 (2020).","journal-title":"CJC Open."},{"key":"27544_CR10","doi-asserted-by":"publisher","first-page":"e626182","DOI":"10.3389\/fped.2020.626182","volume":"8","author":"JC McMurray","year":"2020","unstructured":"McMurray, J. C. et al. Multisystem Inflammatory Syndrome in Children (MIS-C), a post-viral myocarditis and systemic vasculitis-A critical review of its pathogenesis and treatment. Front. Pediatr. 8, e626182 (2020).","journal-title":"Front. Pediatr."},{"key":"27544_CR11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tim.2020.10.004","volume":"28","author":"NN Brodsky","year":"2020","unstructured":"Brodsky, N. N. et al. The mystery of MIS-C post-SARS-CoV-2 infection. Trends Microbiol. 28, 956\u2013958 (2020).","journal-title":"Trends Microbiol."},{"key":"27544_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.cell.2020.09.034","volume":"183","author":"CN Gruber","year":"2020","unstructured":"Gruber, C. N. et al. Mapping systemic inflammation and antibody responses in Multisystem Inflammatory Syndrome in Children (MIS-C). Cell 183, 982\u2013995.e914 (2020).","journal-title":"Cell"},{"key":"27544_CR13","doi-asserted-by":"crossref","unstructured":"Lee PY, et al. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J. Clin. Investig. 130, 5942\u20135950 (2020).","DOI":"10.1172\/JCI141113"},{"key":"27544_CR14","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255\u20132273 (2020).","journal-title":"N. Engl. J. Med."},{"key":"27544_CR15","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-020-1054-6","volume":"26","author":"MJ Carter","year":"2020","unstructured":"Carter, M. J. et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat. Med. 26, 1701\u20131707 (2020).","journal-title":"Nat. Med."},{"key":"27544_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.thromres.2020.04.041","volume":"191","author":"FA Klok","year":"2020","unstructured":"Klok, F. A. et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb. Res. 191, 148\u2013150 (2020).","journal-title":"Thromb. Res."},{"key":"27544_CR17","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1182\/bloodadvances.2020003471","volume":"4","author":"C Diorio","year":"2020","unstructured":"Diorio, C. et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 4, 6051\u20136063 (2020).","journal-title":"Blood Adv."},{"key":"27544_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George, J. N. & Nester, C. M. Syndromes of thrombotic microangiopathy. N. Engl. J. Med. 371, 654\u2013666 (2014).","journal-title":"N. Engl. J. Med."},{"key":"27544_CR19","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.3389\/fped.2019.00133","volume":"7","author":"CC Dvorak","year":"2019","unstructured":"Dvorak, C. C. et al. Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management. Front. Pediatr. 7, e133 (2019).","journal-title":"Front. Pediatr."},{"key":"27544_CR20","doi-asserted-by":"publisher","first-page":"eabf7570","DOI":"10.1126\/sciimmunol.abf7570","volume":"6","author":"L Vella","year":"2020","unstructured":"Vella, L. et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci. Immunol. 6, eabf7570 (2020).","journal-title":"Sci. Immunol."},{"key":"27544_CR21","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1172\/JCI140970","volume":"130","author":"C Diorio","year":"2020","unstructured":"Diorio, C. et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J. Clin. Investig. 130, 5967\u20135975 (2020).","journal-title":"J. Clin. Investig."},{"key":"27544_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/jpids\/piaa161","volume":"10","author":"EM Anderson","year":"2021","unstructured":"Anderson, E. M. et al. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) antibody responses in children with Multisystem Inflammatory Syndrome in Children (MIS-C) and mild and severe Coronavirus Disease 2019 (COVID-19). J. Pediatr. Infect. Dis. Soc. 10, 669\u2013673 (2021).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"27544_CR23","doi-asserted-by":"publisher","first-page":"e28693","DOI":"10.1002\/pbc.28693","volume":"67","author":"C Diorio","year":"2020","unstructured":"Diorio, C. et al. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. Pediatr. Blood Cancer 67, e28693 (2020).","journal-title":"Pediatr. Blood Cancer"},{"key":"27544_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejheart.2003.12.015","volume":"6","author":"C Hall","year":"2004","unstructured":"Hall, C. Essential biochemistry and physiology of (NT-pro)BNP. Eur. J. Heart Fail 6, 257\u2013260 (2004).","journal-title":"Eur. J. Heart Fail"},{"key":"27544_CR25","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.3389\/fgene.2019.00858","volume":"10","author":"E Ulgen","year":"2019","unstructured":"Ulgen, E. et al. pathfindR: an R package for comprehensive identification of enriched pathways in omics data through active subnetworks. Front. Genet. 10, e858 (2019).","journal-title":"Front. Genet."},{"key":"27544_CR26","doi-asserted-by":"publisher","first-page":"5936","DOI":"10.4049\/jimmunol.160.12.5936","volume":"160","author":"M Aste-Amezaga","year":"1998","unstructured":"Aste-Amezaga, M. et al. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J. Immunol. 160, 5936\u20135944 (1998).","journal-title":"J. Immunol."},{"key":"27544_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cyto.2019.03.018","volume":"119","author":"M Mizuta","year":"2019","unstructured":"Mizuta, M. et al. Clinical significance of serum CXCL9 levels as a biomarker for systemic juvenile idiopathic arthritis associated macrophage activation syndrome. Cytokine 119, 182\u2013187 (2019).","journal-title":"Cytokine"},{"key":"27544_CR28","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne, C. B. et al. The immunology of macrophage activation syndrome. Front. Immunol. 10, e119 (2019).","journal-title":"Front. Immunol."},{"key":"27544_CR29","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","volume":"76","author":"C Bracaglia","year":"2017","unstructured":"Bracaglia, C. et al. Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 76, 166\u2013172 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"27544_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","volume":"12","author":"AA Grom","year":"2016","unstructured":"Grom, A. A. et al. Macrophage activation syndrome in the era of biologic therapy. Nat. Rev. Rheumatol. 12, 259\u2013268 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"27544_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/bjh.16299","volume":"189","author":"S Yuan","year":"2020","unstructured":"Yuan, S. et al. Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis. Br. J. Haematol. 189, 72\u201383 (2020).","journal-title":"Br. J. Haematol."},{"key":"27544_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","volume":"75","author":"A Ravelli","year":"2016","unstructured":"Ravelli, A. et al. 2016 classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann. Rheum. Dis. 75, 481\u2013489 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"27544_CR33","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/annrheumdis-2020-217470","volume":"80","author":"GS Schulert","year":"2021","unstructured":"Schulert, G. S. et al. Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-\u03b3 hyper-responsiveness and risk for macrophage activation syndrome. Ann. Rheum. Dis. 80, 617\u2013625 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"27544_CR34","doi-asserted-by":"publisher","first-page":"e11776","DOI":"10.1371\/journal.pone.0011776","volume":"5","author":"R Higgs","year":"2010","unstructured":"Higgs, R. et al. Self protection from anti-viral responses\u2013Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS ONE 5, e11776 (2010).","journal-title":"PLoS ONE"},{"key":"27544_CR35","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.4049\/jimmunol.0804121","volume":"182","author":"R Yoshimi","year":"2009","unstructured":"Yoshimi, R. et al. Gene disruption study reveals a nonredundant role for TRIM21\/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts. J. Immunol. 182, 7527\u20137538 (2009).","journal-title":"J. Immunol."},{"key":"27544_CR36","doi-asserted-by":"publisher","first-page":"eabh2259","DOI":"10.1126\/sciimmunol.abh2259","volume":"6","author":"L Ma","year":"2021","unstructured":"Ma, L. et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci. Immunol. 6, eabh2259 (2021).","journal-title":"Sci. Immunol."},{"key":"27544_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","volume":"50","author":"MJ McGeachy","year":"2019","unstructured":"McGeachy, M. J. et al. The IL-17 family of cytokines in health and disease. Immunity 50, 892\u2013906 (2019).","journal-title":"Immunity"},{"key":"27544_CR38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0092-8674(00)80438-9","volume":"91","author":"T Imai","year":"1997","unstructured":"Imai, T. et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91, 521\u2013530 (1997).","journal-title":"Cell"},{"key":"27544_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/01.ATV.0000095360.62479.1F","volume":"24","author":"H Umehara","year":"2004","unstructured":"Umehara, H. et al. Fractalkine in vascular biology. Arterioscler. Thromb. Vasc. Biol. 24, 34\u201340 (2004).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"27544_CR40","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood-2014-05-573543","volume":"124","author":"LH Boudreau","year":"2014","unstructured":"Boudreau, L. H. et al. Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood 124, 2173\u20132183 (2014).","journal-title":"Blood"},{"key":"27544_CR41","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1056\/NEJMc1804312","volume":"378","author":"N Kitano","year":"2018","unstructured":"Kitano, N. et al. Patient age and the seasonal pattern of onset of Kawasaki\u2019s disease. N. Engl. J. Med. 378, 2048\u20132049 (2018).","journal-title":"N. Engl. J. Med."},{"key":"27544_CR42","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s10753-006-9007-x","volume":"29","author":"J Lindbom","year":"2005","unstructured":"Lindbom, J. et al. Interferon gamma-induced gene expression of the novel secretory phospholipase A2 type IID in human monocyte-derived macrophages is inhibited by lipopolysaccharide. Inflammation 29, 108\u2013117 (2005).","journal-title":"Inflammation"},{"key":"27544_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0014-5793(92)81136-A","volume":"310","author":"M Ponzoni","year":"1992","unstructured":"Ponzoni, M. et al. Stimulation of receptor-coupled phospholipase A2 by interferon-gamma. FEBS Lett. 310, 17\u201321 (1992).","journal-title":"FEBS Lett."},{"key":"27544_CR44","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1172\/JCI117009","volume":"93","author":"T Wu","year":"1994","unstructured":"Wu, T. et al. Interferon-gamma induces the synthesis and activation of cytosolic phospholipase A2. J. Clin. Investig. 93, 571\u2013577 (1994).","journal-title":"J. Clin. Investig."},{"key":"27544_CR45","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","volume":"4","author":"S Jodele","year":"2020","unstructured":"Jodele, S. et al. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 4, 1166\u20131177 (2020).","journal-title":"Blood Adv."},{"key":"27544_CR46","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10875-020-00789-4","volume":"40","author":"NJ Gloude","year":"2020","unstructured":"Gloude, N. J. et al. Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy. J. Clin. Immunol. 40, 699\u2013707 (2020).","journal-title":"J. Clin. Immunol."},{"key":"27544_CR47","doi-asserted-by":"publisher","first-page":"e001868","DOI":"10.1161\/JAHA.115.001868","volume":"4","author":"E Berry","year":"2015","unstructured":"Berry, E. et al. Matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase A2 to modulate inflammation and fever. J. Am. Heart Assoc. 4, e001868 (2015).","journal-title":"J. Am. Heart Assoc."},{"key":"27544_CR48","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1172\/jci.insight.144455","volume":"6","author":"MS Abers","year":"2021","unstructured":"Abers, M. S. et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 6, e11 (2021).","journal-title":"JCI Insight"},{"key":"27544_CR49","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.4049\/jimmunol.1202341","volume":"191","author":"M Sj\u00f6strand","year":"2013","unstructured":"Sj\u00f6strand, M. et al. Expression of the immune regulator tripartite-motif 21 is controlled by IFN regulatory factors. J. Immunol. 191, 3753\u20133763 (2013).","journal-title":"J. Immunol."},{"key":"27544_CR50","doi-asserted-by":"publisher","first-page":"e28931","DOI":"10.1002\/pbc.28931","volume":"68","author":"S Lacinel Gurlevik","year":"2021","unstructured":"Lacinel Gurlevik, S. et al. Hemophagocytosis in bone marrow aspirates in multisystem inflammatory syndrome in children. Pediatr. Blood Cancer 68, e28931 (2021).","journal-title":"Pediatr. Blood Cancer"},{"key":"27544_CR51","first-page":"1133","volume":"34","author":"EM Behrens","year":"2007","unstructured":"Behrens, E. M. et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 34, 1133\u20131138 (2007).","journal-title":"J. Rheumatol."},{"key":"27544_CR52","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/art.22416","volume":"56","author":"J Bleesing","year":"2007","unstructured":"Bleesing, J. et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheumatol. 56, 965\u2013971 (2007).","journal-title":"Arthritis Rheumatol."},{"key":"27544_CR53","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","volume":"2","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2, e358\u2013e367 (2020).","journal-title":"Lancet Rheumatol."},{"key":"27544_CR54","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1002\/art.41616","volume":"73","author":"LA Henderson","year":"2021","unstructured":"Henderson, L. A. et al. American College of Rheumatology Clinical Guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol. 73, e13\u2013e29 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"27544_CR55","doi-asserted-by":"publisher","first-page":"e103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris, P. A. et al. The REDCap consortium: building an international community of software platform partners. J. Biomed. Inf. 95, e103208 (2019).","journal-title":"J. Biomed. Inf."},{"key":"27544_CR56","unstructured":"CDC. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19); 2020. https:\/\/emergency.cdc.gov\/han\/2020\/han00432.asp."},{"key":"27544_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1611391","volume":"376","author":"A Kaddourah","year":"2016","unstructured":"Kaddourah, A. et al. Epidemiology of acute kidney injury in critically ill children and young adults. N. Engl. J. Med. 376, 11\u201320 (2016).","journal-title":"N. Engl. J. Med."},{"key":"27544_CR58","unstructured":"R Studio Team. RStudio: Integrated Development for R. Boston, MA: PBC; 2020."},{"key":"27544_CR59","first-page":"2579","volume":"9","author":"L Van der Maaten","year":"2008","unstructured":"Van der Maaten, L. & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn. Res. 9, 2579\u20132605 (2008).","journal-title":"J. Mach. Learn. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27544-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27544-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T02:14:35Z","timestamp":1675995275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-27544-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,10]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["27544"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-27544-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.13.21255439","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,10]]},"assertion":[{"value":"24 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DTT serves on advisory boards for Janssen, Sobi, and BEAM. HB has stock ownership in Kriya Therapeutics. SH serves on the advisory board for Horizon Pharma. MPL is an advisory board member for Octapharma and Shionogi, a consultant for Amgen, Novartis, Shionogi, Dova, Bayer, the United States Department of Justice, Sobi, Principia and Argenx and has received research funding from Sysmex, Novartis, Astra Zeneca Rigel, Principia, Argenx, Janssen, and Dova, and has served as a medical advisor for Rigel, Principia, the Platelet Disorder Support Association, CdLS Foundation and 22q11.2 Society. KES received personal fees from Elsevier, Enzyvant and Immune Deficiency Foundation. HB is a paid consultant for Kriya Therapeutics. EMB receives research funding from AB2Bio. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. is an inventor on a patent (US patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7222"}}